Gilead agrees 127-country remdesivir licence with generic makers

Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Roche secures rights to potential COVID-19 drug

22 October 2020 Swiss pharmaceutical company Roche will pay $350 million for the rights to develop and distribute an investigational COVID-19 antiviral outside of the US.

Big Pharma

Gilead continues oncology expansion with Tizona deal

22 July 2020 Gilead Sciences is continuing its expansion into the field of cancer therapeutics with the purchase of a 49.9% stake in California-based biotechnology company Tizona.

Biotechnology

Junshi licenses COVID-19 antibody tech from Lonza

14 July 2020 China’s Junshi Biosciences has licensed technology to produce an antibody against COVID-19 from Swiss biotechnology firm Lonza.